TriVascular Technologies, Inc. to Present at the Canaccord Genuity Growth Conference


SANTA ROSA, Calif., July 29, 2015 (GLOBE NEWSWIRE) -- TriVascular Technologies, Inc. (Nasdaq:TRIV), manufacturer of the Ovation Prime® Abdominal Stent Graft System, today announced that its management will be presenting at the Canaccord Genuity Growth Conference on August 12, 2015 in Boston.

TriVascular management is scheduled to present at 8:00am ET. Interested individuals can access the live audio webcast on the investor relations section of the Company's website at: http://www.trivascular.com. The webcast will be available on the Company's website for two weeks following completion of the presentation.

About TriVascular Technologies, Inc. - TriVascular is a medical device company developing and commercializing innovative technologies to significantly advance minimally invasive treatment of abdominal aortic aneurysms. The company manufactures the Ovation Prime Abdominal Stent Graft System, the lowest profile FDA-approved EVAR system, which utilizes a novel, polymer-based sealing mechanism. TriVascular is based in Santa Rosa, California.

For more information visit www.trivascular.com


            

Contact Data